BofA is moving to No Rating on Inari Medical (NARI) after Stryker agreed to acquire Inari for $4.9B, or $80 in cash per share. Given the deal announcement, the firm believes that the stock is no longer trading on fundamentals.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NARI:
- Inari Medical downgraded to Market Perform from Outperform at William Blair
- Inari Medical price target raised at Piper after agreeing to be acquired
- Inari Medical downgraded to Hold from Buy at Canaccord
- Inari Medical downgraded to Hold from Buy at Deutsche Bank
- Inari Medical downgraded to Neutral from Outperform at Baird